Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection
Open accessThe DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Abstract
Modulation of a specific prostanoid synthase or receptor provides therapeutic alternatives to non-steroidal anti-inflammatory drugs (NSAIDs) for treating cyclooxygenase-2 (COX-2 or PTGS2)-governed pathological conditions. Among the COX-2 downstream signaling pathways, the prostaglandin E2 (PGE2) receptor EP2 subtype (PTGER2) is emerging as a crucial mediator of many physiological and pathological events. Genetic ablation strategies and recent advances in chemical biology provide tools for a better understanding of EP2 signaling. In the brain, the EP2 receptor modulates some beneficial effects including neuroprotection in acute models of excitotoxicity, neuroplasticity, and spatial learning via cAMP/PKA signaling. Conversely, EP2 activation accentuates chronic inflammation mainly through the cAMP/Epac pathway, likely contributing to delayed neurotoxicity. EP2 receptor activation also engages β-arrestin in a G protein-independent pathway that promotes tumor cell growth and migration. Understanding the conditions under which multiple EP2 signaling pathways are engaged might suggest novel therapeutic strategies targeting this key inflammatory prostaglandin receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells
Subbaramaiah, K., Hudis, C. A., Chang, S.-H., Hla, T., & Dannenberg, A. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705409200 · Cited by 96 · cited 1×
“For example, aromatase-dependent estrogen synthesis is associated with hormone-dependent breast carcinogenesis, and EP2 can regulate cytochrome P450 aromatase via the cAMP/PKA/ CREB pathway [71].”
RetractedDonnini, S., Finetti, F., Solito, R., Terzuoli, E., Sacchetti, A., Morbidelli, L., Patrignani, P., & Ziche, M. (2007) · The FASEB Journal · doi:10.1096/fj.06-7581com · Cited by 96 · cited 3×
“In the periphery, EP2 activation can improve survival of gastrointestinal epithelial cells after radiation injury, via transactivation of EGFR and enhancement of PI3K/Akt signaling cascade, which suppresses translocation of the proapoptotic protein bax to the mitochondrial membrane, thus abrogating a prominent apoptot…”
RetractedImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 2×
“COX-2 and its derived prostanoids have attracted substantial attention for their possible roles in tumor progression and angiogenesis [53-57].”
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996) · Cell · doi:10.1016/s0092-8674(00)81988-1 · Cited by 2,366
Inflammation and cancer: how hot is the link?
Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., & Sethi, G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.029 · Cited by 1,312 · cited 2×
“As a major inflammatory mediator derived from COX-2, PGE2 via EP2 can induce many pro-inflammatory mediators including cytokines, chemokines, iNOS, and COX-2 itself, which then facilitate cell proliferation, cell survival, angiogenesis, invasion, and metastasis [64, 74].”
Greenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Lehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., & Vartanian, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432609100 · Cited by 1,052 · cited 1×
“It is now clear that microglia are major cellular culprits of EP2-mediated chronic inflammation and neuronal damage [82], because only glia, particularly microglia, express TLR4 [87], which is activated by LPS or proteins released from nearby injured neurons to initiate an innate immune response via CD14 [88].”
Saijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L., Rosenfeld, M. G., Gage, F. H., & Glass, C. K. (2009) · Cell · doi:10.1016/j.cell.2009.01.038 · Cited by 957
Wang, D. (2006) · Gut · doi:10.1136/gut.2004.047100 · Cited by 899
Cited by
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 893
Restoring metabolism of myeloid cells reverses cognitive decline in ageing
Minhas, P. S., Latif-Hernandez, A., McReynolds, M. R., Durairaj, A. S., Wang, Q., Rubin, A., Joshi, A. U., He, J. Q., Gauba, E., Liu, L., et al. (2021) · Nature · doi:10.1038/s41586-020-03160-0 · Cited by 526
Inflammation and depression: a causal or coincidental link to the pathophysiology?
Leonard, B. E. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.69 · Cited by 409
Astrocytes in the initiation and progression of epilepsy
Vezzani, A., Ravizza, T., Bedner, P., Aronica, E., Steinhäuser, C., & Boison, D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00727-5 · Cited by 272
Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside
Dey, A., Kang, X., Qiu, J., Du, Y., & Jiang, J. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.001 · Cited by 215
“Several potent and selective antagonists for EP2 receptor have been developed in the past few years (Figure 2C) [52,55].”
BackgroundSelf-citation
Metadata
- Authors
- Jiang, J., & Dingledine, R.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 34
- Issue
- 7
- Pages
- 413-423
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2059126872
- Cited by
- 166
- References
- 130
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. https://app.cochat.ai/papers/10.1016/j.tips.2013.05.003
- The paper
- Jiang, J., & Dingledine, R. (2013). Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2013.05.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.